This disclosure relates to methods for detection and measurement of anti-drug antibodies (ADAs) against Factor XI and/or Factor XIa therapeutic antibodies, e.g., in a subject being treated with said Factor XI and/or Factor XIa therapeutic antibodies.

The present invention provides antibodies and fragments thereof that specifically detect the complex of a specific cognate antigen-binding moiety, in particular antibodies, and its antigen. The antibodies of the present disclosure do not bind either said cognate antigen binding moiety or said antigen alone and this can be used e.g. to directly detect antigen-bound antigen-binding moieties. Further disclosed are methods for production and use of said antibodies and antibody fragments.

An allergen-immobilized carrier is for use in allergy testing, which carrier is capable of simultaneously measuring multiple items of allergen-specific IgE antibodies with a high sensitivity even when the amount of sample smaller than that used conventionally is used, and capable of performing the measurement with a high correlation with the measured values obtained using ImmunoCAP. The carrier is an allergen-immobilized carrier for use in allergy testing, characterized in that the allergen(s) is/are immobilized on the carrier at a density of from 120 to 500 ng/cm.sup.2.

The present invention relates anti-microbial antibody signatures of inflammatory bowel disease and their use in early and accurate diagnosis of disease including ulcerative colitis (UC) and Crohn's disease (CD).

The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.

One aspect as reported herein is a method for detecting a rat antibody in a serum or plasma sample (obtained) from a mouse comprising the steps of a) providing the sample to be analyzed, b) incubating said serum or plasma sample with an antibody that specifically binds to rat IgG and that does not specifically bind to mouse IgG, wherein the antibody is i) a mixture of an antibody binding to rat kappa light chain and an antibody binding to rat lambda light chain, or ii) a mixture of an antibody binding to rat IgG1 with an avidity of 4.110.sup.10 M.sup.1 or more, an antibody binding to rat IgG2a with an avidity of 8.610.sup.9 M.sup.1 or more, an antibody binding to rat IgG2b with an avidity of 6.410.sup.10 M.sup.1 or more and an antibody binding to rat IgG2c with an avidity of 9.510.sup.10 M.sup.1 or more, c) optionally incubating said sample with a reagent appropriate for the selective detection of total, active or antigen-bound rat antibody, and d) correlating the complex formed in (b) or (c) to the concentration of the rat antibody in the sample.

The present disclosure is directed to human monoclonal IgE antibodies, and IgG antibodies engineered therefrom. Such engineered antibodies can be used to blunt pathologic IgE responses in subjects, such as in the treatment or prevention of allergies.

The invention provides anti-idiotypic antibodies against anti-PD-L1 antibodies and methods of using the same.

The present disclosure is directed to human monoclonal IgE antibodies, and IgG antibodies engineered therefrom. Such engineered antibodies can be used to blunt pathologic IgE responses in subjects, such as in the treatment or prevention of allergies.

The present invention concerns methods for treating progressive multiple sclerosis (MS) in a patient, and an article of manufacture with instructions for such use.